A citation-based method for searching scientific literature

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf, Takashi Seto, Byoung Chul Cho, Manish R Patel, Chao-Hua Chiu, Thomas John, Koichi Goto, Christos S Karapetis, Hendrick-Tobias Arkenau, Sang-We Kim, Yuichiro Ohe, Yu-Chung Li, Young K Chae, Christine H Chung, Gregory A Otterson, Haruyasu Murakami, Chia-Chi Lin, Daniel S W Tan, Hans Prenen, Todd Riehl, Edna Chow-Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R Wilson, Robert C Doebele. Lancet Oncol 2020
Times Cited: 153



Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noe, Peter N Morcos, Tony Mok. N Engl J Med 2017
Times Cited: 1156




List of shared articles



Times cited

Post-chemotherapy and targeted therapy imaging of the chest in lung cancer.
B W Carter, M Altan, G S Shroff, M T Truong, I Vlahos. Clin Radiol 2022
1

Central Nervous System Metastases.
Edwin Nieblas-Bedolla, Jeffrey Zuccato, Harriet Kluger, Gelareh Zadeh, Priscilla K Brastianos. Hematol Oncol Clin North Am 2022
2

Performance of Japanese patients in registrational studies.
Yasushi Goto, Sayaka Arakawa, Masayuki Shirasawa, Ryoko Higashiyama, Keisuke Baba, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida,[...]. Jpn J Clin Oncol 2022
0

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
Aaron C Tan, Daniel S W Tan. J Clin Oncol 2022
9

Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis.
Aaron C Tan, Sze Huey Tan, Siqin Zhou, Solange Peters, Giuseppe Curigliano, Daniel S W Tan. Cancer Treat Rev 2022
0

A Need for More Molecular Profiling in Brain Metastases.
Erica Shen, Amanda E D Van Swearingen, Meghan J Price, Ketan Bulsara, Roeland G W Verhaak, César Baëta, Brice D Painter, Zachary J Reitman, April K S Salama, Jeffrey M Clarke,[...]. Front Oncol 2022
0

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
A S Mansfield, Z Wei, R Mehra, A T Shaw, C H Lieu, P M Forde, A E Drilon, E P Mitchell, J J Wright, N Takebe,[...]. NPJ Precis Oncol 2022
1

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).
María Martínez-García, Sonia Servitja Tormo, Noelia Vilariño Quintela, Ana Arance Fernández, Alfonso Berrocal Jaime, Blanca Cantos Sánchez de Ibargüen, Sonia Del Barco Berrón, Rosario García Campelo, Regina Gironés Sarrió, Juan Manuel Sepúlveda-Sánchez. Clin Transl Oncol 2022
1

Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies.
Sebastian Rubino, Daniel E Oliver, Nam D Tran, Michael A Vogelbaum, Peter A Forsyth, Hsiang-Hsuan Michael Yu, Kamran Ahmed, Arnold B Etame. Front Oncol 2022
0

Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
David J Benjamin, Alyson Haslam, Jenny Gill, Vinay Prasad. Cancer Med 2022
0

Novel targeted therapies for advanced non-small lung cancer.
Omar Abughanimeh, Anahat Kaur, Badi El Osta, Apar Kishor Ganti. Semin Oncol 2022
0

Molecular lung cancer: How targeted therapies and personalized medicine are re-defining cancer care.
Zachary L Quinn, Julie A Barta, Jennifer M Johnson. Am J Med Sci 2022
0

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022
0

Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2022
1

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
37

[Brain metastases-Interdisciplinary approach towards a personalized treatment].
S Grau, M Herling, C Mauch, N Galldiks, H Golla, M Schlamann, A H Scheel, E Celik, M Ruge, R Goldbrunner. Chirurg 2021
0

Genomic profiling in non-small-cell lung cancer in young patients. A systematic review.
D Viñal, D Martínez, O Higuera, J de Castro. ESMO Open 2021
6

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2021
64

Systemic Therapy for Mutation-Driven NSCLC.
Lova Sun, Melina E Marmarelis, Corey J Langer. Semin Radiat Oncol 2021
1

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations.
David König, Spasenija Savic Prince, Sacha I Rothschild. Cancers (Basel) 2021
23

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
3

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021
8

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021
10

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.
Sergey V Orlov, Aglaya G Iyevleva, Elena A Filippova, Alexandra M Lozhkina, Svetlana V Odintsova, Tatiana N Sokolova, Natalia V Mitiushkina, Vladislav I Tiurin, Elena V Preobrazhenskaya, Alexandr A Romanko,[...]. Transl Oncol 2021
2

Treatment of Rare Mutations in Patients with Lung Cancer.
Tarek Taha, Rasha Khoury, Ronen Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya. Biomedicines 2021
1

Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
Alexander Drilon, Michael Duruisseaux, Ji-Youn Han, Masaoki Ito, Christina Falcon, Soo-Ryum Yang, Yonina R Murciano-Goroff, Haiquan Chen, Morihito Okada, Miguel Angel Molina,[...]. J Clin Oncol 2021
10

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Justin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S Baik, Robert C Doebele, Philippe A Cassier, Gilberto Lopes, Daniel S W Tan,[...]. Lancet Oncol 2021
39

Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.
Michael J Grant, Roy S Herbst, Sarah B Goldberg. Nat Rev Clin Oncol 2021
18

Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
Matthew K Stein, Oluchukwu Oluoha, Kruti Patel, Ari VanderWalde. J Pers Med 2021
4

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.
Edouard Dantoing, Nicolas Piton, Mathieu Salaün, Luc Thiberville, Florian Guisier. Int J Mol Sci 2021
7

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
81

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.
Pamela Abdayem, David Planchard. Eur Respir Rev 2021
0

First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly.
Tania Losanno, Cesare Gridelli. Curr Oncol Rep 2021
0

Toward personalized treatment approaches for non-small-cell lung cancer.
Meina Wang, Roy S Herbst, Chris Boshoff. Nat Med 2021
30

The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer.
Alice Mogenet, Laurent Greillier, Pascale Tomasini. Pharmgenomics Pers Med 2021
1

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy.
Olga Rodak, Manuel David Peris-Díaz, Mateusz Olbromski, Marzenna Podhorska-Okołów, Piotr Dzięgiel. Cancers (Basel) 2021
10

Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy.
Jiyun Lee, Myung-Ju Ahn. Cancer Treat Rev 2021
2

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers.
Noura J Choudhury, Jaime L Schneider, Tejas Patil, Viola W Zhu, Debra A Goldman, Soo-Ryum Yang, Christina J Falcon, Andrew Do, Yunan Nie, Andrew J Plodkowski,[...]. JTO Clin Res Rep 2021
3


Longstocking, LLC. © 2021
Home | About Us | FAQs | Terms & Privacy